Rothschild & Co Asset Management US’s Elevance Health ELV Stock Holding History

Rothschild & Co Asset Management US’s Portfolio ELV Stock Details ELV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-2,722	Closed	-$512K	–	414
2017 Q2	$512K	Sell	2,722 -286	-10%	-$51.4K	0.01%	503
2017 Q1	$497K	Sell	3,008 -898	-23%	-$143K	0.01%	491
2016 Q4	$562K	Sell	3,906 -322	-8%	-$43.1K	0.01%	493
2016 Q3	$530K	Buy	4,228 +573	+16%	+$74K	0.01%	429
2016 Q2	$480K	Buy	3,655 +1,070	+41%	+$146K	0.01%	413
2016 Q1	$359K	Buy	2,585 +818	+46%	+$109K	0.01%	404
2015 Q4	$246K	Buy	+1,767	New	+$243K	﹤0.01%	442
2014 Q1	–	Sell	-105,043	Closed	-$9.71M	–	365
2013 Q4	$9.71M	Sell	105,043 -810	-0.8%	-$72K	0.22%	173
2013 Q3	$8.85M	Buy	+105,853	New	+$9.07M	0.19%	181

Other funds holding ELV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

GCM

Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return

Rothschild & Co Asset Management US's ELV Position: Q3 2017 in Review

Rothschild & Co Asset Management US sold out of Elevance Health (ELV) in Q3 2017, closing a stake of 2,722 shares — an estimated $512K sold.

Rothschild & Co Asset Management US first reported a position in ELV in Q3 2013 and held it in 9 quarters. The position peaked at $9.71M in Q4 2013. 845 funds tracked by Wall St. Rank hold ELV as of Q3 2017.

Rothschild & Co Asset Management US reported no remaining Elevance Health position as of Q3 2017 after selling out during the quarter.
Rothschild & Co Asset Management US sold 2,722 Elevance Health shares in Q3 2017, an estimated $512K.
Rothschild & Co Asset Management US first reported a position in Elevance Health in Q3 2013 and held it in 9 quarters.
Rothschild & Co Asset Management US's Elevance Health position peaked at $9.71M in Q4 2013.
845 funds tracked by Wall St. Rank held Elevance Health as of Q3 2017.

Based on Rothschild & Co Asset Management US's 13F filing for Q3 2017, filed 8 Nov 2017.